Finanzen von Cognition Therapeutics Inc (CGTX)CGTXCognition Therapeutics Inc

Evaluating the bottom line, Cognition Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -83.76%, provide a clear picture of how effectively CGTX converts its operational activities into shareholder value.

In the context of the broader market, CGTX competes directly with industry leaders such as CSBR and OSTX. With a market capitalization of $66.33M, it holds a significant position in the sector. When comparing efficiency, CGTX's gross margin of N/A stands against CSBR's 50.54% and OSTX's N/A. Such benchmarking helps identify whether Cognition Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Cognition Therapeutics has shown a narrowing net loss, with Q2 2026 reporting a loss of $3.9 million compared to $6.7 million in Q2 2025. However, the company has consistently reported negative earnings, with EPS figures indicating losses ranging from -0.18 to -0.04 over the past quarters.